Adaptimmune Therapeutics

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ADAP and other ETFs, options, and stocks.

About ADAP

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 

CEO
Adrian Rawcliffe
CEOAdrian Rawcliffe
Employees
494
Employees494
Headquarters
Abingdon, Oxfordshire
HeadquartersAbingdon, Oxfordshire
Founded
2014
Founded2014
Employees
494
Employees494

ADAP Key Statistics

Market cap
175.00M
Market cap175.00M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
480.06K
Average volume480.06K
High today
$1.09
High today$1.09
Low today
$1.01
Low today$1.01
Open price
$1.08
Open price$1.08
Volume
226.54K
Volume226.54K
52 Week high
$5.95
52 Week high$5.95
52 Week low
$1.01
52 Week low$1.01

Analyst ratings

57%

of 7 ratings
Buy
28.6%
Hold
57.1%
Sell
14.3%

ADAP Earnings

-$0.30
-$0.15
-$0.01
$0.14
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Expected Nov 3, Pre-Market
ActualExpected Nov 3, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC.